We also appreciate the interest of Dr. Krebs and colleagues in our study. The suggestion of an individual sensitivity to cannabis is interesting, and we would welcome further studies that examine this issue. However, we do not agree with the suggestion made by Dr. Krebs et al. that their findings contradicted our results. First, it remains unclear whether the samples they examined were representative of schizophrenia patients in general. Second, the authors do not state whether they adjusted the differences in age at onset between cannabis-sensitive patients and the remaining patients (or between cannabis users and nonusers) for gender. Finally, since the findings reported by Krebs et al. are significant (p=0.04) or almost significant (p=0.07), they seem to support, rather than contradict, our findings.